2m 2m 2m 2m 2m 2m 2m
ARS Pharma (SPRY)
NASDAQ
$10.27-$0.01 (-0.14%)
Price as of Jun 23, 2026 7:59 PM EDT- $991.0MMarket Cap
- -39.77%1-Year Change
- BiotechnologyIndustry
ARS Pharma (SPRY)
$10.27-$0.01 (-0.14%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 72.2M +895.07% | 7.3M +24,083.33% | 30,000 -97.72% | 1.3M +1,141.51% | |
Cost of Revenue | 4.8M +1,883.82% | 241,000 -86.58% | 1.8M N/A | N/A N/A | |
Gross Profit | 67.4M +861.09% | 7.0M +497.17% | -1.8M -234.19% | 1.3M +1,141.51% | |
Sales and Marketing Expense | 475,000 +2.15% | 465,000 -50.53% | 940,000 N/A | N/A N/A | |
Research and Development Expense | -2.3M -88.48% | -19.6M -3.38% | -20.3M +10.29% | -18.4M -70.12% | |
Depreciation and Amortization Expense | 1.4M +1,630.38% | 79,000 +8.22% | 73,000 -77.12% | 319,000 -59.26% | |
Total Operating Expenses | 263.7M +185.94% | 92.2M +36.54% | 67.5M +83.40% | 36.8M -58.89% | |
Operating Profit | -179.4M +5,720.56% | -3.1M -95.43% | -67.5M +90.11% | -35.5M -60.35% | |
Interest Income | 10.7M N/A | N/A N/A | 0 +100.00% | -140,000 N/A | |
Interest Expense | N/A N/A | N/A N/A | N/A N/A | -600,000 N/A | |
Interest Income and Expense and Net | 10.7M N/A | 0 N/A | 0 +100.00% | -740,000 N/A | |
Total Nonoperating Income and Expense | 8.1M -29.02% | 11.4M -13.58% | 13.2M +1,477.34% | 834,000 +686.79% | |
Income before Taxes | -171.4M -2,168.28% | 8.3M +112.27% | -67.5M +90.11% | -35.5M -60.35% | |
Income Taxes | -80,000 -127.78% | 288,000 N/A | 0 N/A | 0 N/A | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -171.3M -2,241.76% | 8.0M +114.71% | -54.4M +56.75% | -34.7M -61.24% | |
Net Income from Continuing Operations Applicable to Common | -171.4M -2,168.28% | 8.3M +115.24% | -54.4M +56.75% | -34.7M -61.24% | |
Basic EPS and Net Income | -1.74 -2,275.00% | 0.08 +114.04% | -0.57 -34.48% | -0.87 -66.02% | |
Diluted EPS and Net Income | -1.74 -2,275.00% | 0.08 +114.04% | -0.57 -34.48% | -0.87 -66.02% | |
Basic Weighted Average Shares | 98.6M +1.68% | 96.9M +1.81% | 95.2M +138.30% | 40.0M +14.40% | |
Diluted Weighted Average Shares | 98.6M -3.74% | 102.4M +7.54% | 95.2M +138.30% | 40.0M +14.40% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 41.3M -18.69% | 50.8M -28.40% | 71.0M -66.29% | 210.5M -17.13% | |
Short-Term Investments | 203.7M -22.62% | 263.2M +67.23% | 157.4M +146.45% | 63.9M -1.42% | |
Cash and Cash Equivalents and Short-Term Investments | 245.0M -21.98% | 314.0M +37.51% | 228.4M -16.77% | 274.4M -13.94% | |
Total Current Assets | 284.9M -14.78% | 334.3M +44.26% | 231.7M -16.56% | 277.7M +6.20% | |
Accumulated Depreciation | N/A N/A | 200,000 +65.29% | 121,000 +152.08% | 48,000 -98.31% | |
Property and Plant and Equipment and Net | 2.5M +139.55% | 1.0M +79.27% | 574,000 +74.47% | 329,000 -85.13% | |
Total Long-Term Assets | 2.8M -10.53% | 3.1M +388.09% | 638,000 -78.45% | 3.0M +33.86% | |
Total Assets | 327.7M -6.69% | 351.2M +50.59% | 233.2M -17.14% | 281.4M -15.60% | |
Income Taxes Payable | N/A N/A | N/A N/A | 4,000 -97.70% | 174,000 N/A | |
Total Short-Term Debt | N/A N/A | N/A N/A | N/A N/A | 0 N/A | |
Total Current Liabilities | 39.1M +67.00% | 23.4M +880.34% | 2.4M -56.08% | 5.4M -63.44% | |
Total Long-Term Debt | 96.4M N/A | N/A N/A | N/A N/A | 0 N/A | |
Total Long-Term Liabilities | 97.5M +6,264.49% | 1.5M +4,040.54% | 37,000 -98.81% | 3.1M -34.77% | |
Total Liabilities | 213.4M +126.16% | 94.4M +3,786.12% | 2.4M -71.60% | 8.5M -56.50% | |
Retained Earnings | -294.6M +138.92% | -123.3M -6.09% | -131.3M +70.66% | -76.9M -58.68% | |
Total Stockholders Equity | 114.3M -55.51% | 256.8M +11.28% | 230.8M -15.44% | 272.9M -13.04% | |
Total Shares Outstanding | 99.3M +1.36% | 98.0M +1.60% | 96.4M +2.63% | 93.9M +167.59% | |
Cash Flow | |||||
Cash from Operating Activities | -170.9M -1,361.19% | 13.5M +122.86% | -59.3M +47.88% | -40.1M -39.97% | |
Capital Expenditures | 339,000 -39.79% | 563,000 +221.71% | 175,000 -12.06% | 199,000 -85.50% | |
Cash from Investing Activities | 56.8M +153.50% | -106.1M +21.70% | -87.2M +43,709.05% | -199,000 -99.70% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 104.6M +44.47% | 72.4M +949.41% | 6.9M -96.38% | 190.7M +30,963.84% | |
Financials Ratio | |||||
Gross Margin | 93.38% -3.41% | 96.68% +101.64% | -5,886.67% N/A | N/A N/A | |
Operating Margin | -248.57% +484.94% | -42.49% -99.98% | -225,066.67% +8,239.56% | -2,698.78% N/A | |
Return on Assets | -50.47% -1,943.74% | 2.74% +112.96% | -21.13% +87.30% | -11.28% N/A | |
Return on Equity | -92.33% -2,914.25% | 3.28% +115.20% | -21.59% +82.60% | -11.82% N/A | |
Revenue Growth | 895.07% -96.28% | 24,083.33% +24,745.14% | -97.72% -108.56% | 1,141.51% N/A | |
Current Ratio | 7.28 -48.97% | 14.26 -85.28% | 96.92 +89.99% | 51.01 N/A | |
Cash Ratio | 1.06 -51.31% | 2.17 -92.70% | 29.68 -23.24% | 38.67 N/A | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | N/A N/A | 0.00 N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | N/A N/A | 0.00 N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow